Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
21/05/2024 | 22:05 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:IMMX | Immix Biopharma Inc |
20/05/2024 | 23:27 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IMMX | Immix Biopharma Inc |
20/05/2024 | 23:27 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:IMMX | Immix Biopharma Inc |
20/05/2024 | 23:25 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IMMX | Immix Biopharma Inc |
09/05/2024 | 22:27 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IMMX | Immix Biopharma Inc |
07/02/2024 | 23:15 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:IMMX | Immix Biopharma Inc |
28/11/2023 | 16:48 | InvestorsHub NewsWire | Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing | NASDAQ:IMMX | Immix Biopharma Inc |
10/11/2023 | 01:57 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:IMMX | Immix Biopharma Inc |
29/09/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:IMMX | Immix Biopharma Inc |
25/09/2023 | 22:15 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:IMMX | Immix Biopharma Inc |
30/08/2023 | 22:15 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:IMMX | Immix Biopharma Inc |
23/08/2023 | 22:26 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IMMX | Immix Biopharma Inc |
25/07/2023 | 14:42 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting | NASDAQ:IMMX | Immix Biopharma Inc |
17/07/2023 | 15:37 | GlobeNewswire Inc. | Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial | NASDAQ:IMMX | Immix Biopharma Inc |
10/07/2023 | 15:47 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site | NASDAQ:IMMX | Immix Biopharma Inc |
26/06/2023 | 15:49 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial | NASDAQ:IMMX | Immix Biopharma Inc |
22/06/2023 | 15:53 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors | NASDAQ:IMMX | Immix Biopharma Inc |
20/06/2023 | 15:45 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors | NASDAQ:IMMX | Immix Biopharma Inc |
16/06/2023 | 15:43 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors | NASDAQ:IMMX | Immix Biopharma Inc |
14/06/2023 | 13:30 | GlobeNewswire Inc. | Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program | NASDAQ:IMMX | Immix Biopharma Inc |
13/06/2023 | 23:27 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:IMMX | Immix Biopharma Inc |
12/06/2023 | 15:49 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors | NASDAQ:IMMX | Immix Biopharma Inc |
08/06/2023 | 12:06 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:IMMX | Immix Biopharma Inc |
26/05/2023 | 15:53 | GlobeNewswire Inc. | Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site | NASDAQ:IMMX | Immix Biopharma Inc |
21/05/2023 | 22:05 | GlobeNewswire Inc. | Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial | NASDAQ:IMMX | Immix Biopharma Inc |
21/05/2023 | 22:00 | GlobeNewswire Inc. | Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial | NASDAQ:IMMX | Immix Biopharma Inc |
12/05/2023 | 23:01 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:IMMX | Immix Biopharma Inc |
04/05/2023 | 18:30 | GlobeNewswire Inc. | Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) | NASDAQ:IMMX | Immix Biopharma Inc |
03/05/2023 | 14:00 | GlobeNewswire Inc. | Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab | NASDAQ:IMMX | Immix Biopharma Inc |
26/04/2023 | 23:30 | GlobeNewswire Inc. | Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | NASDAQ:IMMX | Immix Biopharma Inc |